iPS Cells & Regenerative Medicine– category –
-
Bayer Continues Support for BlueRock Therapeutics’ CLARICO Eye Study of iPSC-Derived Photoreceptor Therapy OpCT-001 for Genetic Ocular Disease
TipRanks USA Overview Bayer AG announced continued support for BlueRock Therapeutics' CLARICO eye study, a Phase 1/2a trial evaluating the safety and early efficacy signals of OpCT-001, an iPSC-derived photoreceptor progenitor cell thera... -
BlueRock Therapeutics Advances iPSC-Derived Dopamine Neuron Therapy bemdaneprocel to Phase 3 for Parkinson’s, Demonstrating Significant Motor Improvement in Early Data
RegenMed Review USA Overview BlueRock Therapeutics' iPSC-derived dopamine neuron therapy, bemdaneprocel, is progressing to a Phase 3 trial (exPDite-2) for Parkinson's disease. Earlier 36-month Phase 1 data showed clinically meaningful im... -
FDA Lifts Clinical Hold on Intellia Therapeutics’ Phase 3 Trial for nex-z in Transthyretin Amyloidosis
Intellia Therapeutics (via LinkedIn) USA Overview Intellia Therapeutics announced the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE-2 clinical trial for nexiguran ziclumeran (nex-z), a therapeutic candidate for transthyretin ... -
Intellia Therapeutics’ Gene-Editing Therapy lonvo-z Achieves 87% Reduction in HAE Attacks and 62% Attack-Free Rate in Phase 3 Trial
The Motley Fool USA Overview Intellia Therapeutics announced its in vivo gene-editing therapy, lonvoguran ziclumeran (lonvo-z), successfully met all primary and secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HA... -
Vertex Pharmaceuticals’ CASGEVY Receives FDA Label Expansion for Over 5,500 US Children with Sickle Cell and Beta-Thalassemia, Driving Soaring Sales
ScanX USA Overview Vertex Pharmaceuticals' gene therapy, CASGEVY (exagamglogene autotemcel), received FDA label expansion for patients aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This... -
Vertex Pharmaceuticals Initiates Phase 3 Trial for iPSC Islet Cell Therapy VX-880 for Type 1 Diabetes, Showing High Rates of Insulin Independence
Facebook (Breakthrough T1D) USA Overview Vertex Pharmaceuticals has launched a Phase 3 clinical trial for zimislecel (VX-880), its stem cell-derived islet cell therapy for severe type 1 diabetes. Prior trials demonstrated remarkable effi... -
Editas Medicine Stock Soars 14.4% on Q2 Revenue Beat, Investor Focus on Gene-Editing Pipeline Intensifies
MarketBeat USA Overview Editas Medicine reported a Q2 2026 revenue of $11.89 million, significantly surpassing analyst estimates of $2.85 million, alongside an adjusted EPS loss of $0.15, better than the projected $0.27 loss, leading to ... -
Regenerative and Gene Therapies for Rare Diseases Achieve Key Clinical Milestones, Including iPSC for Retinitis Pigmentosa and Gene Therapy for Pediatric Hearing Loss
RegMedNet UK Overview Significant clinical milestones have been reached in regenerative and gene therapies for rare diseases. Sumitomo Pharma America has dosed the first patient in a Phase I/IIa trial of its iPSC-derived cell therapy for... -
3D Bioprinting Advances Tumor Organoid Modeling and Bone Regeneration Spheroids
PMC - NIH USA Overview 3D bioprinting technology is revolutionizing cancer modeling by enabling the construction of human tumor organoids that accurately recapitulate complex tumor microenvironments for high-throughput drug screening. Co... -
Extracellular Vesicles Emerge as Promising Biomarkers and Therapeutics for Cardiovascular Disease
Exosome-RNA.com USA Overview Researchers at Massachusetts General Hospital have highlighted the significant potential of extracellular vesicles (EVs) as both diagnostic biomarkers and therapeutic agents for cardiovascular diseases (CVD)....
